Anti-Complement C5 Antibody (Crovalimab)
Catalog No.
F1201
Anti-Complement C5 Antibody (Crovalimab)
Featured Products
Crovalimab (SKY59; RO7112689) is a humanized antibody against C5 in a pH-dependent manner with KD of 15.2nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds to human FcRn with high affinity (KD: 17 μM; pH 6.0). Crovalimab blocks the cleavage of C5 by C5 convertase and inhibits the activity of a C5 variant (p.Arg885His). Crovalimab significantly inhibits the formation of C5b-9 in all three complement pathways, the classical pathway (CP), the lectin pathway (LP), and the alternative pathway (AP). Crovalimab has the potential to be used in the study of paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases.
Quality Control & DataSheet
- View current batch:
-
Purity > 90% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
145 kDa
Dry ice
1917321-26-6
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
SKY59, RG6107, RO7112689
100 mM Pro 20 mM Arg pH 5.0. No preservative!
P01031
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Complement C5
Please avoid freeze-thaw cycles.